Women who are carriers of the ornithine transcarbamylase (OTC) mutation are at risk for developing hyperammonemia during the postpartum period and at times of metabolic stress. We present a unique case of hyperammonemic coma occurring in an OTC mutation carrier during the antepartum period. Multiple factors, including the administration of antenatal corticosteroids, likely precipitated this critical condition. Clinicians should be aware of this lifethreatening clinical presentation and be prepared to identify, treat, and prevent hyperammonemia in affected individuals.
Introduction
Inborn errors of metabolism are a rare cause of hyperammonemic coma. Ornithine transcarbamylase (OTC) is an enzyme of the urea cycle, which converts the toxic ammonia molecule to non-toxic, water-soluble urea.
1,2 OTC deficiency is an X-linked disorder that results in hyperammonemia and has been associated with cases of postpartum encephalopathy in carriers. 1, 3 Here we present a unique case of hyperammonemic coma occurring during the antepartum period in an OTC mutation carrier.
Case
A 26-year-old gravida 3 para 1010 presented to an outside hospital at 33 weeks gestation with complaints of fever, nausea, vomiting and contractions. She was a known heterozygous carrier for a familial mutation of the OTC gene. She had one prior first trimester miscarriage and one term live-born male infant who died 7 days after birth due to complications from OTC deficiency. DNA analysis confirmed that he was hemizygous for the OTC c.482A>G (p.N161S) mutation. She had one brother, two sisters and one nephew who died in the neonatal period, but their mutation carrier statuses could not be verified. The patient had immigrated to the United States from India and was a vegetarian for cultural reasons with no other history of dietary restrictions, developmental delay or symptomatic episodes of hyperammonemia. During this pregnancy, she had undergone chorionic villus sampling with molecular testing that demonstrated an unaffected male fetus.
At the outside hospital, the patient was suspected to be in preterm labor and was treated with terbutaline and betamethasone. Over 4 days, her mental status progressively deteriorated. She was given intravenous haloperidol for agitation and subsequently became dystonic and unresponsive. The patient was transferred to our hospital in critical condition. Upon arrival, she was unresponsive with agonal breathing and a Glasgow Coma Scale score of 3. She was intubated and transferred to the intensive care unit. External monitoring showed uterine contractions every 4 to 5 min and minimal fetal heart rate variability. Her labor was augmented, and she rapidly delivered a 2240 g infant with APGAR scores of 7 at 1 min and 8 at 5 min.
Initial investigations sought to exclude an acute cerebrovascular event as the cause of her coma, but both head computerized tomography and magnetic resonance imaging were normal. Her urine toxicology screen was negative. When the patient's ammonia level of 213 mmol l À1 (7 to 35) returned, hyperammonemia due to her OTC carrier status was strongly suspected as the cause. Confirmatory plasma and urine amino-acid levels were sent for analysis, demonstrating a plasma glutamine level of 1118 mmol l À1 (205 to 756) and a urine orotic acid level of 5.6 mmol mol À1 creatinine (0.4 to 1.2). Her initial serum glucose was 63 mg dl À1 . Importantly, no underlying infectious source could be found. Blood, urine, sputum and cerebrospinal fluid cultures were negative; PCR for influenza A and B was negative; and placental pathology revealed no evidence of chorioamnionitis.
Treatment of our patient's hyperammonemia began with dextrose-containing IV fluids and lactulose, but her ammonia levels continued to rise. Continuous venovenous hemofiltration was initiated along with intravenous sodium benzoate, an ammonia scavenger. The patient was started on protein-free total parenteral nutrition to meet caloric needs and to prevent endogenous protein catabolism. Within 36 h of treatment, her ammonia levels decreased substantially (range 56 to 125 mmol l
À1
). On hospital day 4, she became arousable and was able to follow simple commands. She was transitioned to oral sodium phenylbutyrate and placed on a protein-restricted diet. Her mental status steadily improved and she was discharged home on hospital day 18. Six weeks following her discharge, the patient was mentally and neurologically intact and her ammonia levels remained normal.
Comment
The urea cycle is a series of enzymatic reactions responsible for detoxification of nitrogenous waste derived from protein catabolism. Defects in any portion of the urea cycle can result in hyperammonemia and its clinical manifestations. OTC deficiency is the most common of the urea cycle disorders with an estimated incidence of approximately one in 14 000. 4 The majority of women heterozygous for OTC mutations remain asymptomatic; however, 10 to 15% of carriers will become symptomatic during their lifetime. This phenotypic variation is thought to occur due to random inactivation of X chromosomes bearing the mutant allele (lyonization), leading to differing levels of OTC activity among carriers and their tissues. 1, 4, 5 Affected individuals often exhibit symptoms ranging from dietary protein aversion to profound neuropsychiatric manifestations, such as ataxia, seizures and hyperammonemic encephalopathy. 5, 6 Various factors can trigger hyperammonemic crises in individuals with urea cycle disorders, either by increasing the need for nitrogen clearance or by impairing urea cycle enzyme activity in the liver. These stressors include high-protein intake either from a dietary load or total parenteral nutrition (TPN); increased endogenous protein catabolism due to reduced nutritional intake, infection, trauma or steroid administration; and hepatic toxicity from chemotherapy and other medications, such as valproic acid and haloperidol. 2, 4, 5, 6 A number of reports have described hyperammonemic encephalopathy in OTC mutation carriers in the immediate postpartum period, when maternal nitrogen burden is increased by collagen breakdown during uterine involution. 1, 3 In contrast, there are few reports of women with urea cycle enzyme deficiencies developing hyperammonemic coma during pregnancy. In the only reported death associated with OTC deficiency during pregnancy, a previously asymptomatic woman developed fatal hyperammonemic encephalopathy 2 days after receiving amino-acid-containing TPN at 14 weeks gestation for hyperemesis gravidarum. 7 Pregnancy is thought to confer protection against hyperammonemia due to increased nitrogen utilization by the uterus, placenta and fetus, and detoxification of maternal nitrogen by the fetus. 1, 3 Multiple factors, including infection, steroids and haloperidol, may have contributed to hyperammonemia in our patient. Several case reports have implicated infections as catalysts for hyperammonemic episodes in otherwise asymptomatic individuals. Gastroenteritis and intra-amniotic infection were two possible triggers suggested by our patient's clinical presentation, but no infectious source could be identified. Decreased oral intake and inadequate intravenous replacement at the onset of her illness may have increased her endogenous protein catabolism, further contributing to hyperammonemia in this setting.
We further hypothesize that the administration of betamethasone for fetal lung maturity may have induced protein catabolism, resulting in endogenous nitrogen release and worsening hyperammonemia. There have been two reports of nonpregnant OTC mutation carriers who developed hyperammonemic crises following steroid administration. One was a 48-year-old female who received intravenous steroids for a severe asthma attack. She was incorrectly diagnosed with 'steroid psychosis' and lapsed into coma before metabolic encephalopathy was suspected, and her serum ammonia level was found to be markedly elevated. 2 Another was a 36-year-old male who was prescribed oral prednisone for an autoimmune disorder and subsequently developed hyperammonemic encephalopathy. 8 No cases have been previously published describing hyperammonemia following the administration of antenatal corticosteroids.
In addition, our patient's initial mental status changes were treated with haloperidol. Certain medications, including valproic acid and haloperidol, have been known to cause hyperammonemia in patients with urea cycle disorders. Valproate is thought to precipitate hyperammonemia by exerting direct toxic effects on hepatic mitochondria and inhibiting the urea cycle. 6 Haloperidol is thought to exert similar inhibitory effects on urea cycle enzyme activity and was reported to trigger hyperammonemia in a patient with argininosuccinate synthase deficiency. 4 Thus, haloperidol may have exacerbated the hyperammonemia in our patient by impairing her already overwhelmed OTC activity.
The diagnosis of a urea cycle defect should be considered in women with a history of protein aversion, episodic behavioral changes or psychosis and a strong personal or family history of neonatal losses. In addition, clinicians must recognize that OTC mutation carriers remain at risk for developing symptomatic hyperammonemia. Although our patient was a known carrier, her neuropsychiatric symptoms were not recognized as manifestations of hyperammonemia, which delayed appropriate treatment and resulted in administration of medications that may have precipitated or exacerbated her coma. Unexplained coma in this setting should prompt a metabolic work-up with measurement of serum ammonia levels, which are typically >150 mmol l À1 during an acute episode.
For patients presenting with acute hyperammonemic crisis, hemodialysis is the treatment of choice for rapid reduction of ammonia levels. Lactulose may be given to decrease the production of ammonia by the gastrointestinal tract. The ammonia scavengers, sodium phenylbutyrate, sodium benzoate and L-arginine, may be employed to stimulate further removal by alternate pathways. 1, 2, 5 Further management strategies include administration of intravenous fluids containing dextrose to decrease catabolism, serial serum ammonium evaluations and proactive use of ammonia scavengers. Complete avoidance of protein should not exceed 24 to 48 h, after which depletion of essential amino acids results in a catabolic state and endogenous nitrogen production. 3 Although previous reports have described postpartum hyperammonemic coma in women heterozygous for OTC mutations, we report the first case of a carrier who presented with coma in the antepartum period that was not precipitated by an exogenous protein load. Physicians should exercise caution with the use of corticosteroids and TPN in known OTC mutation carriers and consider close monitoring of ammonia levels following their administration, as well as in the immediate postpartum period. Prompt diagnosis and treatment of infection, including routine screening for asymptomatic bacteriuria, may prevent significant hyperammonemia. Timely reduction of hyperammonemia is crucial to averting long-term neurologic morbidity and mortality. We support a multidisciplinary approach in managing women with OTC mutations, including high-risk obstetric care, medical genetics, genetic counseling and dietary consultations.
